Cipla Limited
CIPLA
Rangering i aksjer
#1814
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Aksjekurs
$14.61
Sist synkronisert: 2026-10-19
Markedsverdi
$11.81B
Endring (1 dag)
-0.11%
Endring (1 år)
-21.65%
Land
IN
Handel Cipla Limited (CIPLA)
Kategori
Healthcare
Antall utestående aksjer for Cipla Limited (CIPLA)
Antall utestående aksjer per June 2026: 807.63M
Ifølge Cipla Limited sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 807.63M. Ved slutten av March 2024 hadde selskapet 807.35M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Cipla Limited (CIPLA) fra 2004 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 807.63M | -0.07% |
| 2025 | 808.17M | 0.10% |
| 2024 | 807.35M | 0.04% |
| 2023 | 807.01M | 0.04% |
| 2022 | 806.67M | 0.04% |
| 2021 | 806.36M | 0.04% |
| 2020 | 806.02M | 0.08% |
| 2019 | 805.36M | 0.07% |
| 2018 | 804.77M | 0.10% |
| 2017 | 803.98M | 0.10% |
| 2016 | 803.14M | 0.03% |
| 2015 | 802.93M | 0.00% |
| 2014 | 802.92M | 0.00% |
| 2013 | 802.92M | 0.00% |
| 2012 | 802.92M | 0.00% |
| 2011 | 802.92M | 1.62% |
| 2010 | 790.14M | 1.65% |
| 2009 | 777.29M | 0.00% |
| 2008 | 777.29M | 0.18% |
| 2007 | 775.93M | 3.50% |
| 2006 | 749.68M | 0.00% |
| 2005 | 749.68M | 0.00% |
| 2004 | 749.65M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 197.09% |
IN
|
